Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy

Abstract

A short diagnosis-to-treatment interval independently predicts inferior outcomes in follicular lymphoma. Using international discovery and validation cohorts, we demonstrate its prognostic value beyond established prognostic indices, with implications for risk stratification, clinical trial design, and interpretation.